GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
of Stockholders on May 25, 2017 (the Annual Meeting), at which a
total of 44,628,818 shares of GenMark common stock, or
approximately 95% of the shares entitled to vote, were
represented in person or by valid proxies. A description of each
matter voted upon at the Annual Meeting is described in detail in
GenMarks definitive proxy statement filed with the Securities and
Exchange Commission on April 13, 2017. Set forth below are final
voting results for the four proposals that were subject to a vote
of GenMarks stockholders at the Annual Meeting.
|
1.
|
For the proposal to elect two nominees for director to
serve a three-year term expiring at GenMarks 2020 Annual Meeting of Stockholders, the voting results were as follows: |
|
Name of Directors Elected
|
For
|
Withhold
|
Broker Non-Votes
|
||||
|
Daryl J. Faulkner
|
35,897,868
|
2,720,351
|
6,010,599
|
||||
|
James Fox, Ph.D.
|
34,252,517
|
4,365,702
|
6,010,599
|
expiring at GenMarks 2018 Annual Meeting of Stockholders: Hany
Massarany and Kevin C. OBoyle.
expiring at GenMarks 2019 Annual Meeting of Stockholders: Lisa M.
Giles and Michael S. Kagnoff.
|
2.
|
For the proposal to ratify Ernst Young LLP as GenMarks
independent registered public accounting firm for the fiscal year ending December 31, 2017, the voting results were as follows: |
|
For
|
Against
|
Abstain
|
||
|
44,611,931
|
13,353
|
3,534
|
|
3.
|
For the proposal to approve, on an advisory basis, the
compensation of GenMarks named executive officers, the voting results were as follows: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
|
25,186,020
|
13,424,536
|
7,663
|
6,010,599
|
|
4.
|
For the proposal to indicate, on an advisory basis, the
preferred frequency with which GenMark should hold future stockholder advisory votes on the compensation of its named executive officers, the voting results were as follows: |
|
1 Year
|
2 Years
|
3 Years
|
Abstain
|
|||
|
37,327,656
|
1,725
|
1,287,600
|
1,238
|
on the compensation of its named executive officers every year
until the next stockholder vote to indicate the preferred
frequency with which GenMark should hold future stockholder
advisory votes on the compensation of its named executive
officers, which will be no later than GenMarks Annual Meeting of
Stockholders in 2023.
Annual Meeting.
About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel. GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Recent Trading Information
GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) closed its last trading session up +0.02 at 12.94 with 208,350 shares trading hands.
